哌拉西林钠他唑巴坦钠联合氨溴索治疗慢性阻塞性肺疾病的临床效果

Clinical Effect of Piperacillin Sodium and Tazobactam Sodium Combined with Ambroxol in the Treatment of Chronic Obstructive Pulmonary Disease

目的研究哌拉西林钠他唑巴坦钠+氨溴索治疗慢性阻塞性肺疾病的临床效果。方法选取2018年9月-2021年7月在我院治疗的82例慢性阻塞性肺疾病患者为研究对象,采用随机数字表法分为对照组和观察组,各41例。对照组采用氨溴索治疗,观察组在对照组基础上联合哌拉西林钠他唑巴坦钠治疗,比较两组临床效果、肺功能指标、降钙素原(PCT)、C反应蛋白(CRP)水平及不良反应发生情况。结果观察组治疗总有效率为92.68%,高于对照组的82.93%,差异有统计学意义(P<0.05);两组呼气峰流速(PEF)、第1秒用力呼气容积(FEV1)、用力肺活量(FVC)均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组PCT、CRP水平均低于对照组,且观察组低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为2.44%,低于对照组的14.63%,差异有统计学意义(P<0.05)。结论哌拉西林钠他唑巴坦钠联合氨溴索治疗慢性阻塞性肺疾病效果显著,可提高治疗效果,改善患者肺功能指标,减轻血清炎症因子水平,不良反应少,是一种安全、有效的治疗方案。

Objective To study the clinical effect of piperacillin sodium and tazobactam sodium+ambroxol in the treatment of chronic obstructive pulmonary disease.Methods A total of 82 patients with chronic obstructive pulmonary disease treated in our hospital from September 2018 to July2021 were selected as the research subjects.They were divided into control group and observation group by random number table method,with 41cases in each group.The control group was treated with ambroxol,and the observation group was treated with piperacillin sodium and tazobactam sodium on the basis of the control group.The clinical effect,pulmonary function indexes,procalcitonin(PCT),C-reactive protein(CRP)levels and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 92.68%,which was higher than 82.93% of the control group,and the difference was statistically significant(P<0.05).The peak expiratory flow(PEF),forced expiratory volume in the first second(FEV1)and forced vital capacity(FVC)of the two groups were higher than those before treatment,and those in the observation group was higher than those in the control group,the difference was statistically significant(P<0.05).The levels of PCT and CRP in the two groups were lower than those in the control group,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 2.44%,which was lower than 14.63% in the control group,and the difference was statistically significant(P<0.05).Conclusion Piperacillin sodium and tazobactam sodium combined with ambroxol is effective in the treatment of chronic obstructive pulmonary disease,which can improve the therapeutic effect,improve the pulmonary function index of patients,reduce the level of serum inflammatory factors,and has less adverse reactions.It is a safe and effective treatment scheme.